AustriaAustria

Intercell starts pivotal Phase II/III study for JE vaccine in India

24.02.2011

Vienna/Hyderabad – Austria vaccine specialist Intercell AG and its Indian manufacturing partner Biological E. Ltd. have started enrolment of a Phase II/III study in children of 1-3 years of age for Intercell’s preventive vaccine against Japanese Encephalitis (JE). The vaccine, which is manufactured in India by Biological E. has been already safety tested on 20 adults, is based on Intercell's technology. This randomized and controlled study will be the first pivotal Phase II/III study in an endemic region towards licensure of the paediatric JE vaccine and aims at investigating safety and immunogenicity compared to a licensed competitor Japanese Encephalitis vaccine in healthy children. Following the approval and launch of Intercell's vaccine against Japanese Encephalitis for adult travellers and military personnel in Europe, the USA and Australia, the development of a vaccine to protect children in endemic areas from Japanese Encephalitis has been a major goal of the company. Japanese Encephalitis (JE) is a deadly infectious disease found mainly in Asia. Approximately 30,000 to 50,000 cases of JE are reported in Asia each year, and the actual number of cases is likely much higher due to under-reporting in rural areas. JE is fatal in approximately 30 percent of those who show symptoms and leaves half of survivors with permanent brain damage. In 2005, Intercell and Biological E. signed a contract for the development, manufacturing, marketing and distribution in India and the Indian subcontinent of Intercell's Japanese Encephalitis vaccine. The vaccine's further regulatory approval route for other Asian territories is expected through the World Health Organization – Novartis will be responsible for the marketing and distribution in these regions.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

AustriaAustria

03.11.2010

Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/intercell-starts-pivotal-phase-iiiii-study-for-je-vaccine-in-india.html

Product of the week

Products

Events

All Events

Current issue

All issues